B
one marrow transplantation can be carried out successfully between donors and recipients who have ABO incompatibilities, provided that measures are taken to avoid acute hemolytic reactions after the transfusion of incompatible red cells (RBCs). 1, 2 There are two types of ABO incompatibility. One type, referred to as minor, may involve hemolysis after the destruction of a proportion of the patient's RBCs by the anti-A or anti-B present in the small quantity of plasma contained in the graft. The other type, referred to as major, involves the systemic presence in the recipient of ABO antibodies against the RBC antigens of the donor. These antibodies will mediate severe acute hemolytic reactions if the incompatible RBCs are not removed from the graft.
We present a case of massive delayed hemolysis of the recipient's RBCs by donor-derived ABO antibodies after peripheral blood progenitor cell (PBPC) transplant with minor ABO incompatibility. This hemolysis was probably due to recall immunity in relation to previous pregnancies of the donor, in the context of an extremely precocious recovery of donor-derived white cells, which is a result of the very rapid hematopoietic engraftment associated with PBPCs and the use of granulocyte-colony-stimulating factor (G-CSF).
Delayed massive immune hemolysis mediated by minor ABO incompatibility after allogeneic peripheral blood progenitor cell transplantation
CASE REPORT
A 16-year-old boy was diagnosed with acute myeloblastic leukemia M1 according to the FAB classification, with trisomy 8, in the context of back pain as well as multiple febrile episodes that were resistant to antibiotics. He had no other particular antecedent medical problem. He underwent a first course of induction chemotherapy with mitoxantrone, arabinoside-cytosine (ara-C), and etoposide, which resulted in failure, with persistence of 16-percent blast cells in the bone marrow. A second line of treatment based on amsacrine and intermediate-dose ara-C was then administered, but the patient again did not reach a complete remission. In light of this refractory leukemia, an allogeneic transplant was proposed as the therapeutic solution of last resort, in full awareness that it represented only a 10-percent chance of cure. The preparative regimen consisted of ara-C, cyclophosphamide, and an 8-Gy single dose of total body irradiation, with intrathecal administration of methotrexate. Infection prophylaxis was based on trimethoprim/cotrimoxazole, ciprofloxacin, fluconazole, and ganciclovir before transplant, followed by acyclovir after transplant, as well as polyvalent immunoglobulins. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine A alone.
The donor was the patient's mother, who had a major HLA mismatch at the D locus, as well as a different ABO group (donor, O Rh-positive; recipient, A Rh-positive). It should be noted that she had undergone four pregnancies and had received one RBC transfusion. To carry out the transplant, the donor's marrow was stimulated with G-CSF (10 µg/kg) for 5 days and PBPCs were collected by cytapheresis on 2 consecutive days. Erythropoietin, 600 U per kg twice a week, was also given for 3 weeks before and 3 weeks after the transplant, to proceed in parallel with the collection of autologous RBC concentrates for use in the recipient as needed. The return of the unmanipulated PBPCs (12.23 × 10 6 CD34+ cells/kg) proceeded without complication, and, in particular, no acute hemolytic reaction was engendered on Day 0 or Day 1. From that time on, the patient received only filtered and irradiated O Rh-positive RBC concentrates (these being by priority those taken from the donor), as well as group O Rh-positive single-donor platelet concentrates resuspended in group A plasma.
The patient was provided with 5 µg per kg of G-CSF from Day 1 through Day 12 and with 200 U per kg of erythropoietin from Day 1 through Day 33. Neutrophil recovery was prompt, with 0.5 × 10 9 polymorphonuclear neutrophils per L achieved on Day 9 and 2 × 10 9 on Day 10. The platelets never attained a value of 20 × 10 9 per L, as their recovery was hampered by the severe gastrointestinal bleeding observed later. As for the RBC lineage, early signs of recovery were noted by Day 10, with a reticulocyte count of 1 percent, which attained a maximum value of 14 percent on Day 20 before returning to aplastic values thereafter. However, the patient never became independent of transfusion, first because of hemolysis and then because of the gastrointestinal bleeding (see below).
The posttransplant course was first complicated by Staphylococcus epidermidis bacteremia on Day 3. Then, the hemoglobin dropped dramatically from 8.5 g per dL on Day 6 to 4 g per dL on Day 8, without any evidence of bleeding (Fig. 1) . The drop in hemoglobin occurred concomitantly with hematopoietic recovery, which was also accompanied by a major increase in serum bilirubin (556 µmol/L on Day 8) and lactate dehydrogenase (1218 IU/L on Day 9), a complete disappearance of haptoglobin, and a positive direct antiglobulin test. Renal function was maintained. The group A RBCs from the recipient were accordingly destroyed within 36 hours. The recipient was group A until Day 6, showed a mixed-field population with very few group A RBCs among group O cells on Day 7, and was group O from Day 8 on (Table 1) . The anti-A titer in the recipient was 0 through Day 6, 4 on Day 7, and 128 on Day 8. Consequently, there was no agglutination of group A RBCs in the presence of the patient's serum until after Day 6, when there was weak agglutination on Day 7 and 2+ agglutination from Day 8 on. The patient was treated with RBC transfusions, corticosteroids, and four sessions of plasmapheresis. This allowed the hemolysis to resolve rapidly after all the patient's group A RBCs had been destroyed.
In the same period (i.e., Day 6-12), the patient developed acute GVHD, which attained an overall maximum grade of IV on Day 12, including grade III skin GVHD, grade IV hepatic GVHD, and grade IV gastrointestinal GVHD, the latter of which was responsible for massive uncontrollable bleeding that compromised survival. Aggressive therapy in- 
DISCUSSION
The presence in the recipient of ABO antibodies against the RBC antigens of the donor is referred to as major ABO incompatibility. (This was not the case in our patient.) Apart from the risk of acute hemolysis at the time of transplant, there is also the fear that, if progenitor cells express ABO antigens, there could be an additional risk of graft rejection. However, this type of incompatibility does not engender GVHD or prejudice the prognosis for survival. 1, 2 In fact, rather than rejection of the graft, it seems to cause a prolonged RBC aplasia. To prevent complications, it is necessary to process the bone marrow ex vivo to eliminate the RBCs from the graft and in rare cases to carry out pretransplant plasma exchanges in the recipient. [1] [2] [3] [4] In most recipients, the antibodies disappear within 2 to 3 months, but, in those who present with high levels before transplant, there may be a rapid delayed increase in their titer with consecutive RBC aplasia.
Minor ABO incompatibility can be defined by the presence in the donor of ABO antibodies directed against the recipient's RBCs, as observed in our patient. This occurs in approximately 30 percent of marrow transplants and may be somewhat more frequent in the unrelated-donor setting. 5 This situation is of concern only when the plasma antibody titer of the donor is such that it is likely to induce in the patient a hemolytic reaction during the return of the marrow, [which in the latter case the plasma] should be removed. 2 Allogeneic bone marrow transplantation carried out under these conditions can in general be performed without any acute problem. In principle, there is no effect on marrow recovery, no apparent increase in GVHD, and no consequence for the survival of the recipient. However, it appears that a moderate, delayed hemolytic reaction may occur 9 to 16 days after bone marrow transplantation in 10 to 30 percent of the cases. 5, 6 Rarely, massive hemolysis has been reported. 7 Theoretically, a PBPC graft could further increase this hemolytic risk, with regard to its lymphocyteenriched content, 8 but there are no epidemiologic data available to support this.
The patient discussed here never received plasma, with the exception of a small volume at the time of the transplant, which did not produce any significant degree of hemolysis. The serum from the donor, in this case the mother, did not contain any HLA antibodies but did have a substantial anti-A titer (2048), probably induced by her multiple previous pregnancies. An anamnestic immune response may have favored the high titer of A antibodies in the recipient, actively produced by the lymphocytes grafted from the donor. These events were associated with a very precocious marrow recovery and caused a massive destruction of the recipient's RBCs.
Our case is the sixth reported in the literature of hemolysis after allogeneic minor-incompatible PBPC transplantation. [8] [9] [10] [11] [12] Most cases occurred in the context of the transplant of group A PBPCs to group O recipients (Table  2) . Although it theoretically could further increase the risk of hemolysis, a high antibody titer in the donor does not appear to be required for this to happen. This episode, combined with very severe acute GVHD, precipitated the degradation of the general condition of the patient, leading to death. Whereas no HLA antibodies were detected in the mother, the patient developed very severe GVHD immediately after hematologic recovery, despite the classic use of cyclosporine A. Cyclosporine A is capable of stimulating an exaggerated immune response that favors the proliferation of B-lymphocytes, combined with the suppression of the helper T-lymphocytes, which allows for the development of hemolysis. 5, 6 Because of the very high risk of leukemia relapse in this patient, no intravenous methotrexate was given, in the hope of inducing a graft-versus-leukemia effect. The fact that no methotrexate had been received may likewise have contributed to the development of the hemolytic reaction, inasmuch as this medication is toxic to B-lymphocytes and may therefore prevent the production of the antibodies necessary for the occurrence of the passenger lymphocyte syndrome. 5, 8 Indeed, among PBPC cases, only one patient received 2 doses of methotrexate (Table 2) , and GVHD prophylaxis incorporating methotrexate prevented the syndrome after marrow transplantation. 5 The literature likewise makes reference to the fact that methotrexate may prevent hemolysis affecting transfused group O RBCs that is possibly mediated through absorption of A or B antigens on their surface. 5 High doses of intravenous immunoglobulins may also be associated with a brief episode of moder- ate hemolysis immediately after their infusion. 5 All these factors may have contributed to the massive hemolysis that developed in our patient.
Our observation confirms the potential hemolytic risk of using a graft of PBPCs with a minor ABO incompatibility. [8] [9] [10] [11] [12] Two additional considerations may have accentuated the phenomenon in our patient: 1) a gestational sensitization and 2) a high lymphocyte content in the graft. This type of hemolytic reaction could be minimized by the inclusion of methotrexate in the program of GVHD prophylaxis, as well as by the elimination of B-lymphocytes from the graft-for instance, through CD34 selection.
